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Abstract
Background: One goal of personalized medicine is leveraging the emerging tools of data science to guide medical
decision-making. Achieving this using disparate data sources is most daunting for polygenic traits. To this end, we
employed random forests (RFs) and neural networks (NNs) for predictive modeling of coronary artery calcium (CAC),
which is an intermediate endo-phenotype of coronary artery disease (CAD).
Methods: Model inputs were derived from advanced cases in the ClinSeq® discovery cohort (n=16) and the FHS
replication cohort (n=36) from 89th-99th CAC score percentile range, and age-matched controls (ClinSeq® n=16, FHS
n=36) with no detectable CAC (all subjects were Caucasian males). These inputs included clinical variables and
genotypes of 56 single nucleotide polymorphisms (SNPs) ranked highest in terms of their nominal correlation with
the advanced CAC state in the discovery cohort. Predictive performance was assessed by computing the areas under
receiver operating characteristic curves (ROC-AUC).
Results: RF models trained and tested with clinical variables generated ROC-AUC values of 0.69 and 0.61 in the
discovery and replication cohorts, respectively. In contrast, in both cohorts, the set of SNPs derived from the discovery
cohort were highly predictive (ROC-AUC≥0.85) with no significant change in predictive performance upon
integration of clinical and genotype variables. Using the 21 SNPs that produced optimal predictive performance in
both cohorts, we developed NN models trained with ClinSeq® data and tested with FHS data and obtained high
predictive accuracy (ROC-AUC=0.80-0.85) with several topologies. Several CAD and “vascular aging" related biological
processes were enriched in the network of genes constructed from the predictive SNPs.
Conclusions: We identified a molecular network predictive of advanced coronary calcium using genotype data from
ClinSeq® and FHS cohorts. Our results illustrate that machine learning tools, which utilize complex interactions
between disease predictors intrinsic to the pathogenesis of polygenic disorders, hold promise for deriving predictive
disease models and networks.
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Background
Informed medical decision making through the effective
use of clinical and genomic data is one of the promis-
ing elements of personalized precision medicine [1] in
which predictive models enable the assessment of alterna-
tive treatment strategies [2]. Predictive models also play
a pivotal role in utilizing the genomic data for generat-
ing predictions regarding the disease risk and progression
[3–5] with the potential to generate biological insights
into the mechanisms behind complex diseases [6], such
as coronary artery disease (CAD). In CAD, the arteries
of the heart, which supply oxygen rich blood to the car-
diac muscle, lose their ability to function properly due to
atherosclerosis. CAD is a multifactorial disease [7, 8] that
has been associated with many clinical and demographic
variables, and major risk factors such as high blood pres-
sure, high levels of blood lipids, smoking and diabetes.
Our study focuses on coronary artery calcium (CAC),
which is an intermediate endo-phenotype of CAD [9]. The
level of CAC, which is measured by the CAC score, varies
within a broad range in the general population. CAC score
is a strong predictor of lethal cardiac events, including
myocardial infarction (MI) [10–15]. A major objective of
personalized precision medicine is to identify subgroups
of patients that are at the highest risk of cardiovascular
events and accelerated vascular aging, such as patients
with highly advanced CAC, among a large population of
patients at intermediate risk based on standard clinical
variables.
The key mechanism behind coronary artery calcifica-
tion is the phenotypic modulation of vascular cells that is
triggered by stimuli including oxidative stress, increased
rate of cell death [16], and high levels of inflamma-
tory mediators [17]. The genetics behind CAC deposition
is complex. Several important genes involved in vascu-
lar calcification have been previously identified through
mouse model studies [18], studies on rare human dis-
eases that lead to excessive calcification [17], and through
elucidation of its links with bone mineralization [19]. Sev-
eral genome-wide association studies (GWAS) have also
previously focused on CAC [20–25]. Some of the human
genomic loci linked to CAC are 9p21, PHACTR, and
PCSK9 (also linked to CAD and MI [22, 26, 27]). Several
past studies have combined clinical variables and geno-
type data for predicting CAD. Some examples include
implementation of Cox regressionmodels [28–30] and the
use of allele counting, logistic regression, and support vec-
tor machines in [31]. Statistical modeling of CAC as an
intermediate phenotype for CADhas also been the subject
of research in recent years [32, 33].
Recently, there has been increasing interest in the
application of machine learning methods for predict-
ing disease subphenotypes by utilizing genomic fea-
tures [34]. These methods provide increased ability for
integrating disparate sources of data while utilizing inter-
actions (both linear and nonlinear) between genomic fea-
tures (e.g., gene-gene interactions) [35]. Machine learning
methods eliminate the need for multiple testing correc-
tion required in statistical association tests that treat
each predictor separately. They also mitigate potential
biases that could originate from model misspecifica-
tion since machine learning typically aims at identify-
ing model structures that are optimal for the training
data [36].
In this study, we utilized machine learning tools for
predictive modeling of the advanced CAC subphenotype
by integrating clinical variables and genotype data. Our
study focused on identifying predictors of the high-risk
subgroup of CAD patients with advanced CAC among
an intermediate risk sample of middle-aged Caucasian
males. Previous studies have established that higher CAC
scores are observed among men compared to women
[37, 38], as well as a higher prevalence of CAC among
white Americans compared to black Americans [39].
We used the random forest (RF) algorithm, which is a
decision tree based machine learning method [40] estab-
lished as an effective tool for modeling with genomic data
[41] to develop predictive models for the subset of indi-
viduals with advanced CAC. We derived model inputs
(or SNPs) using two feature selection approaches. First,
we leveraged a literature based strategy based on previ-
ous association studies of CAC to define a set of 57 single
nucleotide polymorphisms (SNPs). As an alternative con-
textual approach, we utilized a standard feature selection
and filtering approach in machine learning to identify 56
additional SNPs from the ClinSeq® genotype data [42, 43].
We assessed the predictive performances of these sets of
SNPs with and without clinical variables in the ClinSeq®
cohort. For validation of the observed predictive patterns,
we evaluated these SNP sets in an independent sample set
from the Framingham Heart Study (FHS) and identified
a robust subset of predictive SNPs that performed con-
sistently well in data sets from both cohorts. Using this
subset of SNPs, we developed neural network (NN) mod-
els trained with data from the ClinSeq® discovery cohort
and tested with data from the FHS replication cohort
under a wide range of network topologies, and assessed
the predictive performances of these models. The biolog-
ical processes enriched in the molecular network of genes
constructed from the predictive loci generated insights
into potential mediators of advanced CAC, which is a
distinct subphenotype of vascular disease.
Methods
Overview of the computational analysis
Our overall strategy was to use clinical data and genotype
data for predicting advanced CAC in a discovery cohort,
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and to test if the observed predictive patterns can be con-
firmed in an independent cohort (Fig. 1). We developed
RFmodels that predict advanced CACwithin the ClinSeq®
cohort using traditional risk factors (or clinical variables)
and then derived two sets of SNPs. The first one was a
set of GWAS-identified SNPs (or “SNP Set-1”) previously
associated with CAC, whereas the second set (or “SNP
Set-2”) was derived using genotype data from the ClinSeq®
discovery cohort. In order to limit the number of SNPs in
SNP Set-2, we used a standard feature selection approach
in machine learning [44, 45] and extracted the 56 SNPs
(among 668,427 SNPs) whose genotypes had the highest
Pearson correlation values with the advanced CAC phe-
notype. We assessed the predictive performance by using
only clinical data (to establish a baseline performance) and
only genotype data, as well as their combination.
After assessing the RF based predictive patterns gener-
ated by the clinical variables, SNP Set-1 and SNP Set-2 in
the ClinSeq® discovery cohort, we focused on testing the
most predictive set of SNPs in the FHS replication sam-
ple. Based on the analysis of predictive performance and
replication in both sample sets, we identified the subset of
SNPs that generated optimal performance in RF models
in both cohorts. As an additional validation of the robust-
ness of our findings, we trained and tested NN models
with the genotypes of these SNPs in the ClinSeq® and
FHS cohorts, respectively. Data used in NN models came
from advanced CAC cases and age-matched controls (all
Caucasian males) in both cohorts.
Upon verifying the high predictive performance under
a wide range of NN topologies, we utilized GeneMANIA
[46] to create a functional interaction network composed
of genes on which this subset of SNPs were located, as
well as additional genes known to be most closely related
to these genes. GeneMANIA uses linear regression to
maximize the connectivity between the genes within the
network while minimizing the interactions with the genes
that are excluded. Two types of links between gene pairs
were found to be present in this network: co-expression
(correlated expression levels) and genetic interactions
(effects of a gene perturbation can be changed by a second
perturbed gene). Gene Expression Omnibus (GEO) and
Biological General Repository for Interaction Datasets
(BioGRID) are the main sources of co-expression and
genetic interaction datasets, respectively in the GeneMA-
NIA database. Finally, using the list of genes within this
network derived by GeneMANIA, we performed function
and disease enrichment analysis to demonstrate the rele-
vance of this molecular network to cardiovascular disease
based on existing knowledge in the literature. Figure 2
illustrates the steps taken in our analysis.
CAC scores and binary CAC states
The models we developed in this study aimed at pre-
dicting the binary case-control statuses of age-matched
Caucasian male patients. Hence, we first transformed the
CAC scores (measured by Agatston method [47]) of the
32 Caucasian male subjects from the ClinSeq® study that
Fig. 1 Overall strategy of the analysis
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Fig. 2 Schematic of the modeling approach
formed our discovery cohort (data previously published in
[42, 43]) into binary CAC states. 16 control subjects in this
cohort had zero CAC scores corresponding to state “0",
whereas the 16 age-matched cases had high CAC scores
(ranging between 500 and 4400) corresponding to state
“1". These binary case-control states served as the true
class labels and were later used for training and testing of
the developed classification models. Based on the Multi-
Ethnic Study of Atherosclerosis (MESA) cohort standards
[48, 49], a percentile value for each case was computed
using the online MESA calculator that takes age, gender,
race and CAC score as its inputs. The case subjects in the
ClinSeq® discovery cohort, two of which were diabetic, fell
within the 89th-99th CAC score percentile range.
The replication cohort from FHS comprised of 36 con-
trols and 36 age-matched Caucasian male case subjects
(including three diabetic cases) also within the 89th-99th
CAC score percentile range. As an additional set of com-
parative control groups, 122 cases from FHS within 29th-
88th CAC score range were split into two distinct sets of
61 cases within 29th-68th and 69th-88th percentile ranges
and were age-matched with two sets of 61 subjects with no
CAC. These two equal-sized subcohorts were then used
to test whether the predictive patterns generated by the
discovery (ClinSeq®) and replication (FHS) cohorts were
specific to the 89th-99th percentile CAC score range and
not replicable with lower levels of coronary calcium. Two
classes of model variables were used in this study as pre-
dictors of coronary calcium, namely clinical variables and
genotypic variables, as described below.
Clinical variables
Nine clinical variables available from all subjects in both
cohorts were utilized as predictors of CAC. These vari-
ables included body mass index (BMI), cholesterol levels
(low-density lipoprotein (LDL), high-density lipoprotein
(HDL), and total cholesterol), triglycerides, blood pressure
(systolic and diastolic), fasting blood glucose level, and fib-
rinogen. All subjects were non-smoker Caucasian males
in both ClinSeq® and FHS cohorts. The detailed descrip-
tion of each clinical variable is given in Additional file 1:
Table S1, whereas the mean and standard deviation val-
ues among cases vs. controls, along with their p-values are
listed in Additional file 1: Tables S2 and S3 for ClinSeq®
and FHS cohorts, respectively.
Genotypic variables
We compiled two sets of SNPs using a feature selec-
tion strategy that relied on the existing CAC literature,
as well as the ClinSeq® discovery cohort. The first set of
57 SNPs were reported in previous association studies of
CAC that focused on the presence of CAC rather than its
extreme levels [20–25]. We named this set “SNP Set-1”
(listed in Additional file 1: Table S4 along with the
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reported p-values). From the the ClinSeq® genotype data,
we also generated a second set of 56 SNPs (“SNP Set-2”)
as described above. All SNPs in SNP Set-2 are listed in
Additional file 1: Table S5. Genotypes of the 113 biallelic
SNPs in both SNP sets were coded as 0 or 2 (homozygous
for either allele) or 1 (heterozygous) using the same ref-
erence alleles in both ClinSeq® and FHS cohorts. Details
regarding the genotyping protocols and data sources for
both cohorts are provided in Additional file 2: Supplemen-
tary Text.
Predictive modeling using RFs and NNs
We implemented the RF classification method using the
Statistics and Machine Learning Toolbox TM of Matlab®
[50] for predicting the binary CAC state. Predictive
accuracy is computed by generating receiver operating
characteristic (ROC) curves (true positive rate vs. the
false positive rate obtained using several classifier out-
put thresholds) and by quantifying the areas under these
curves (AUC). Due to the randomized nature of the
classification method, we performed 100 runs (per set
of features or model inputs) and reported the mean
AUC (normality of the AUC distributions not rejected
by Anderson-Darling tests [51]). For each reported AUC
value, we empirically derived a p-value as the fraction of
AUC values in 1000 runs (with randomly permuted case-
control statuses) at or above the mean AUC value gener-
ated when the case-control statuses are not permuted (i.e.,
the actual data). This approach has been previously used
for computing the statistical significance of ROC-AUC
values [32, 52]. For machine learning based classifica-
tion models with two classes (e.g., cases and controls),
the baseline predictive performance from ROC curves is
AUC=0.5 (commonly used AUC threshold in clinical stud-
ies that look at sensitivity and specificity of classifiers [53])
corresponding to a classification likelihood of a coin flip.
For each decision tree, approximately two-thirds of the
data (this ratio varied up to ±15% among different runs)
is retained to be used for model training, whereas the
remaining data is used for model testing. These test
samples are referred to as “out-of-bag” (OOB) samples,
whereas the training samples are expanded by bootstrap-
ping [54] (or sampling with replacement) up to the sample
size of the original data [55] prior to model training. Clas-
sification of the test samples are based on the complete
ensemble of trees (a total of 100 trees) with the “majority
vote” scheme [56]. For example, a test sample is predicted
to be “CAC positive” if the number of trees that predict
“State 1” is higher than the ones that predict “State 0”. Pre-
dictive importance is computed for each input variable
by permuting its values corresponding to the test sub-
jects and finding the change in the prediction error (or the
fraction of incorrectly classified subjects). In mathemati-
cal terms, the prediction error for OOB samples without
permutation (eOOB) is computed as nm,OOB/(nc,OOB +
nm,OOB), where nm,OOB and nc,OOB stand for the numbers
of misclassified and correctly classified samples without
permutation, respectively. Likewise, the prediction error
for OOB samples with permuted input values (eOOB,perm)
is computed as nm,OOB,perm/(nc,OOB,perm + nm,OOB,perm),
where nm,OOB,perm and nc,OOB,perm stand for the numbers
of misclassified and correctly classified samples with per-
mutation, respectively. The difference between the two
error terms (eOOB,perm − eOOB) is computed for each tree
and the average value of this difference (over all trees) is
divided by its standard deviation to identify the predictive
importance of a feature. Features with positive predictive
importance have higher eOOB,perm values in comparison
with their eOOB values.
Features are ranked with respect to their cumulative
predictive importance evaluated from 100 independent
runs, or RF models. Stronger predictors have higher pre-
dictive importance values than weaker predictors. After
ranking all features in each distinct feature set (e.g., all
clinical variables), we decreased the number of features
gradually by leaving out weaker predictors to identify the
optimal predictive performance and the corresponding
optimal set of features. We repeated this procedure to
compare the predictive performances of models trained
and tested by combining clinical and genotype data, as
well as using each layer data in isolation. The predictive
patterns generated by data from the ClinSeq® discovery
cohort were also compared with the patterns generated by
the independent FHS replication cohort. Finally, RF mod-
els were also used to identify a subset of SNPs in SNP Set-2
that generated the optimal predictive performance in both
ClinSeq® and FHS cohorts.
Upon identifying the subset of SNPs in SNP Set-2 that
generate RF models with optimal performance in both
cohorts, we further validated our results by implementing
a neural network (NN) based classification approach using
the NN ToolboxTM of Matlab® [50]. This allowed us to test
whether the cumulative predictive signal captured by RFs
is also captured by a different method that does not rely on
decision trees and to assess the robustness of the predic-
tive signal in our data set. In addition, NN implementation
allowed us to test several network topologies while using
discovery/replication cohort samples for training/testing
these topologies (rather than using the randomized OOB
sampling of RFs). Further details regarding the ratio-
nale behind our RF-NN implementation are provided in
Additional file 2: Supplementary Text.
We trained three-layer feedforward networks using
backpropagation [57] with sigmoid transfer functions in
two hidden layers and a linear transfer function in the
output layer. In both hidden layers, the number of nodes
was varied from one to 20 with increments of one,
thereby leading to a total of 400 network configurations
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individually used for training and testing. In short, the
inputs into each network layer (initial input is the geno-
type data) are weighted and the sum of the weighted
inputs transformed by the transfer functions of the hid-
den layers are used to generate model outputs (or the
case/control status) [58]. We trained all network con-
figurations with the genotypes of the optimal subset of
SNPs within SNP Set-2 from the advanced CAC cases and
age-matched controls in the ClinSeq® discovery cohort.
Approximately 20% of the training samples include the
“validation” samples used for minimizing overfitting dur-
ing training. We subsequently performed model testing
with the genotype data from the advanced CAC cases
and age-matched controls subjects in the FHS replication
cohort.
Predictive accuracy was once again assessed with ROC
curves. For each NN configuration, we computed the
median AUC value (normality of the AUC distributions
rejected by Anderson-Darling tests [51]) among 100 inde-
pendent runs. Once again, we derived an empirical p-
value based on the predictive performance obtained from
1000 runs with randomized case-control statuses.
Results
Models built with clinical variables and SNP Set-1
We first built RF models using all of the nine clinical
variables from the ClinSeq discovery cohort and identi-
fied that three of them had positive predictive importance
values as listed in Table 1. These predictors included
HDL Cholesterol, systolic blood pressure, and fibrino-
gen. Fibrinogen has been previously associated with CAC
[59, 60] as a critical biomarker of inflammation [61] and
atherosclerosis [62]. Within the FHS replication cohort,
five clinical variables including total cholesterol, systolic
and diastolic blood pressure, fibrinogen and fasting blood
glucose (a glycemic trait previously associated with CAC
levels [63]) had positive predictive importance values.
As we varied the number of predictors between one to
nine, the optimal AUC values were 0.69 (p-value=0.015)
and 0.61 (p-value=0.080) for ClinSeq® and FHS cohorts,
respectively (Fig. 3). These AUC values were within the
Table 1 Predictive importance values of clinical variables in
ClinSeq® and FHS cohorts. Only the instances with positive
predictive importance are reported
Clinical variable Predictive importance
Total cholesterol 8.60 (FHS)
Systolic blood pressure 6.24 (FHS), 12.94 (ClinSeq®)
Diastolic blood pressure 2.88 (FHS)
Fibrinogen 1.81 (FHS), 3.50 (ClinSeq®)
Fasting Blood Glucose 0.024 (FHS)
HDL cholesterol 18.39 (ClinSeq®)
1 2 3 4 5 6 7 8 9
0.35
0.4
0.45
0.5
0.55
0.6
0.65
0.7
Number of model inputs
A
U
C
CLIN (ClinSeq)
CLIN (FHS)
Fig. 3 Predictive performance plotted against the number of
predictors in ClinSeq® and FHS cohorts. Model inputs are derived only
from clinical variables
range of 0.60-0.85, which is the previously reported AUC
range compiled from 79 studies predicting CAD or car-
diac events based on the Framingham risk score (FRS)
[64]. Even though our case-control sample was already
stratified by age and gender, the remaining clinical vari-
ables still exhibited modest predictive value.
We next built RF models for the ClinSeq® discovery
cohort using the literature-derived genotypes of the 57
SNPs in “SNP Set-1” as model inputs and identified 17
SNPs with positive predictive importance. To compare the
predictive patterns generated by the discovery and repli-
cation cohorts based on the SNP Set-1 genotype data, we
next developed RF models for the FHS replication cohort
and identified 19 SNPs among SNP Set-1 with positive
predictive importance in this cohort. Top 30 percentile
predictors in SNP Set-1 (i.e., predictive SNPs) gener-
ated AUC ranges of 0.68-0.72 and 0.71-0.78 in ClinSeq®
and FHS cohorts (without clinical variables), respectively.
Only five of the 17 predictive SNPs (29%) from the Clin-
Seq® discovery cohort were predictive in the FHS cohort
pointing to a low degree of replication between the two
cohorts. In order the test whether the combination of the
nine clinical variables and SNP Set-1 resulted in improved
predictive performance, we merged these two groups of
model inputs with the ClinSeq® discovery data set. We
observed a significant improvement in the AUC range
from 0.68-0.72 (only SNP Set-1) to 0.72-0.77 (combined
set of inputs). In contrast, when we used the FHS replica-
tion data set in the same way, AUC range declined from
0.71-0.78 to 0.69-0.75. Hence, the improvement of predic-
tive accuracy we observed within the ClinSeq® discovery
cohort, by adding clinical variables to SNP Set-1, was not
confirmed in the FHS replication cohort.
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Selection of SNP Set-2 based on genotype-phenotype
correlation within the ClinSeq® discovery cohort
Although the literature-based SNP Set-1 provided a use-
ful initial source of model inputs, we recognized that a
potential limitation of this approach was the focus of
past association studies on CAC as a broad and hetero-
geneous phenotype. In contrast, our study aims to derive
an optimal set of predictors for the subset of CAC pos-
itive patients with the most advanced vascular lesions at
the top decile of the broad CAC score range. Accord-
ingly, we employed a standard feature selection approach
to derive an alternative set of genotypes (SNP Set-2)
from the ClinSeq® data that were highly correlated with
the advanced CAC subphenotype (described in Meth-
ods). This approach effectively leverages the capacity of
RF algorithm to eliminate non-informative signals and
sort out input SNPs of potential predictive utility with-
out the multiple-testing penalty. The range of genotype-
phenotype correlation among the SNPs in SNP Set-2
(no overlap with SNP Set-1) was 0.63-0.73 within the
ClinSeq® discovery cohort. Upon incorporating the geno-
types of SNP Set-2 in this cohort into RF models, we
obtained an AUC value of 0.9975. Given this high pre-
dictive performance, our subsequent analyses focused on
further validation and refinement of this set of geno-
types.
Predictive performance of SNP Set-2 in FHS and ClinSeq®
data sets
In order to test whether the high predictive performance
of SNP Set-2 was replicated in the FHS cohort, we trained
and tested RF models using the genotypes of SNP Set-2
in the replication cohort. We identified that the positive
predictive importance values of 30 of the 56 predictive
SNPs (54%) were replicated. We also observed common
patterns between the discovery and replication cohorts
in terms of the predictive importance based rankings of
the 30 SNPs with positive predictive importance in both
cohorts. Nine of the top 18 SNPs overlapped between
the two cohorts, whereas the top two SNPs (rs243170
and rs243172, both on FOXN3) were the same in
both cohorts.
Top 30 SNPs, which were selected based on their pos-
itive predictive importance in both cohorts, generated
AUC ranges of 0.80-0.85 and 0.96-0.99 in the replica-
tion and discovery cohorts, respectively. Hence, SNP Set-2
was highly predictive in both discovery and replication
cohorts. Combining the clinical variables and SNP Set-
2 did not improve the predictive performance in either
cohort. In fact, there was a slight decline in the optimal
AUC from 0.85 to 0.83 in the FHS cohort, whereas no
change in the optimal AUC was observed in the ClinSeq®
cohort with the combination of clinical variables and SNP
Set-2 (Table 2).
One potential explanation of the high predictive perfor-
mance of SNP Set-2, which does not include any SNPs pre-
viously associated with CAC, in both cohorts is the broad
range of CAC levels. Given that SNP Set-2 was derived
from cases with extreme levels of CAC, it remained to be
determined whether the predictive power of SNP Set-2
was specific to this extreme phenotype or whether it could
be generalized to a broader range of CAC levels. Hence,
we tested the collective predictive performance of the 30
SNPs in SNP Set-2 that had positive predictive power in
both cohorts with genotype data from cases with lower
levels of CAC. Among the 61 cases within the 29th-68th
percentile range and the 61 age-matched controls, top 50
percentile markers generated an AUC range of 0.62-0.66.
Utilizing the data from 61 cases within 69th-88th range and
61 age-matched controls, AUC range was approximately
the same (0.61-0.66). These results further extended the
robustness of our findings and demonstrated that the high
predictive performance of SNP Set-2 was only observed in
the 89th-99th percentile CAC score range.
Subset of SNPs in SNP Set-2 with optimal predictive
performance in both cohorts and enrichment analysis
Table 3 shows the list of 21 SNPs in SNP Set-2 gener-
ated optimal predictive performance in ClinSeq® and FHS
cohorts. Using the genotypes of these 21 SNPs, we trained
NN models of 400 distinct topologies with ClinSeq® data
and tested each topology with the FHS data. As shown in
Fig. 4, we obtained 36 model topologies with AUC val-
ues ranging between 0.80-0.85 with empirically derived
p-values of less than 0.05, thereby utilizing a different
machine learning approach to further validate the collec-
tive predictive ability of these SNPs in the FHS replication
cohort. This result demonstrates the stable and consistent
Table 2 Predictive performances of RF models (quantified by the mean ± standard deviation values of AUC) trained and tested with
different predictor sets in the ClinSeq® and FHS cohort data
Predictors Optimal # markers Optimal AUC p-value
CLIN 3 (ClinSeq®), 3 (FHS) 0.69±0.02 (ClinSeq®), 0.61±0.02 (FHS) 0.015 (ClinSeq®), 0.080 (FHS)
SNP Set-2 21 (ClinSeq)®, 21 (FHS) 0.99±0.01 (ClinSeq®), 0.85±0.02 (FHS) <0.001 (ClinSeq®), <0.001 (FHS)
CLIN+SNP Set-2 21 (ClinSeq®), 18 (FHS) 0.99±0.01 (ClinSeq®), 0.83±0.01 (FHS) <0.001 (ClinSeq®), <0.001 (FHS)
“CLIN” corresponds to the nine clinical variables listed in Additional file 1: Table S1 (all variables except age and gender)
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Table 3 Predictive importance values of the set of SNPs that generate optimal predictive performance in both cohorts. Nearest genes
are listed for intergenic SNPs (marked with asterisk)
SNP Locus Predictive importance Predictive importance Percent
(ClinSeq®) (FHS) difference
rs13159307 FBXL17* 28.83 21.64 24.94
rs8107904 EMR2* 36.95 21.83 40.92
rs571797 NRG3 17.68 6.86 61.20
rs2390285 MACC1 22.86 17.27 24.45
rs342393 NRG3 18.04 15.34 14.97
rs13429160 LOC101927701 35.68 16.89 52.66
rs11674863 LOC101927701 26.18 15.74 39.88
rs514237 NRG3 19.09 24.81 23.06
rs6860493 NNT 20.72 26.39 21.49
rs10054519 C5orf28 21.17 25.25 16.16
rs12521249 PAIP1* 21.17 25.44 16.78
rs10065689 NNT 20.45 25.55 19.96
rs2241097 TLR5 34.02 24.11 29.13
rs10059993 NNT-AS1 20.82 24.77 15.95
rs12645809 ANTXR2 22.1 25.33 12.75
rs480220 NRG3 19.76 24.01 17.70
rs1366410 NNT 21.15 23.77 11.02
rs11767632 YAE1D1* 32.09 20.94 34.75
rs7713479 NNT-AS1 21.11 37.48 43.68
rs243172 FOXN3 34.90 46.17 24.41
rs243170 FOXN3 35.91 51.20 29.86
The normalized difference of the predictive importance values of each SNP in two cohorts (difference divided by the higher predictive importance value in the two cohorts)
has a median value of 24% (interquartile range:17%-36%). In terms of predictive importance based ranking, five of the top 11 SNP predictors (with 65% of the cumulative
predictive importance) are common, whereas nine of the top 14 SNP predictors (with 76% of the cumulative predictive importance) overlap between two cohorts
*Intergenic SNPs for which the nearest genes are reported
0.8 0.81 0.82 0.83 0.84 0.85
0.02
0.025
0.03
0.035
0.04
0.045
0.05
AUC
p−
va
lu
e
Fig. 4 Properties of 36 optimal NN models trained with data from the
discovery cohort and tested with data from the replication cohort.
Median AUC value for each network topology (ranging between
0.8021 and 0.8515) and the corresponding p-values. Third quartile of
the AUC values among different network topologies ranged between
0.8503 and 0.9074
features of these 21 SNPs in predicting advanced CAC
independent of the classifier strategy employed. The opti-
mal NN topologies have 9-20 nodes in their first hidden
layers and 6-20 nodes in their slightly less complex second
hidden layers.
We identified a total of 13 genes that included the 21
SNPs leading to optimal predictive performance in both
cohorts. Using GeneMANIA, we derived a molecular net-
work that included this group of 13 genes in addition
to the 18 genes known to be linked to the first group
based on coexpression and genetic interaction data from
the literature [46]. Figure 5 shows this network, whereas
the abbreviated gene symbols and the corresponding gene
names are listed in Additional file 1: Table S6. The pro-
teins coded by the genes in the network have a wide range
of roles. Twelve of them are either a transcription factor
or an enzyme, one is a translational regulator, and two are
transmembrane receptors.
In order to identify whether gene list was enriched
in any biological functions or processes associated with
CAD, we used two bioinformatics resources, namely
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Fig. 5 Network of genes derived from GeneMANIA (based on 244
studies in humans) using the most predictive set of SNPs in this study.
The connections in pink are derived from gene coexpression data,
whereas the connections in green are derived from genetic
interaction data from the literature. The inner circle is composed of
genes on which the subset of SNPs in SNP Set-2 leading to optimal
performance in both cohorts are present, whereas the genes forming
the outer circle are additional genes identified by GeneMANIA. The
thicknesses of the links (or edges) between the genes are
proportional to the interaction strengths, whereas the node size for
each gene is proportional to the rank of the gene based on its
importance (or gene score) within the network. All interactions within
this network are listed in Additional file 1: Table S8
Database for Annotation, Visualization and Integrated
Discovery (DAVID) [65] and Ingenuity Pathway Anal-
ysis (IPA, Qiagen, Redwood City, CA, USA). Through
their associations with blood magnesium levels, type-2
tumor necrosis factor receptors, HDL cholesterol, BMI,
CAD, and adiponectin, 17 of the 31 genes in our net-
work are associated with only one disease class, namely
cardiovascular disease with a 1.9 fold-enrichment and
a p-value of 0.0025 (modified Fisher’s exact test) based
on DAVID and the Genetic Association Database. Fur-
thermore, through mouse and rat models, six genes in
our network (ARID5B, CYB5R4, EGLN1, RETN, TLR5,
and NRG3) have been previously associated with several
CAC risk factors including diabetes, insulin resistance,
LDL cholesterol, and triglycerides (all associations listed
in Additional file 2: Supplementary Text). Table 4 and
Additional file 1: Table S7 show the cardiovascular disease
related biological functions and phenotypes (identified
by IPA based on Fisher’s exact test with p-value<0.05),
that are enriched within our network. Several biological
processes enriched among the network genes are associ-
ated with “vascular aging” (further discussion in the next
section).
Discussion
A major goal in the cardiovascular disease field is iden-
tifying individuals who are at greatest risk of accelerated
CAD pathogenesis and complications, such as stroke and
MI. Recognizing that the utility of traditional risk factors
(particularly those driven by age) is not sufficiently robust
to identify all patient groups with accelerated CAD [66],
incorporating genomic data into machine learning tools
for building predictive models of CAD is a promising area
with potential clinical applications in future studies [2]. To
this end, our study has demonstrated the utility of using
a machine learning approach to identify a panel of SNPs
predictive of a complex polygenic trait observed among a
high-risk subset of patients. The resulting set of SNPs gen-
erated higher performance over traditional risk factors in
predicting advanced CAC in a replicable manner in two
independent cohorts.
In a previous study [33], authors combined clinical vari-
ables with 13 predictive SNPs from 13 different genes
(identified among 2882 candidate SNPs from 231 genes
that were proposed by a group of MESA investigators)
for predicting the presence of coronary calcium using a
Bayesian approach. None of these 13 SNPs were included
in SNP Set-1 since they were not associated with CAC in
a past GWAS or meta-analysis. Likewise, SNP Set-2 did
not include any of these SNPs since their genotypes in
the ClinSeq discovery cohort were not correlated highly
enough with the binary advanced CAC state to pass our
feature selection filter. A key difference between our study
and [33] is the severity of the CAC scores among case
subjects. The cases in [33] had CAC scores around 50th
percentile (based on the reported average age and CAC
score), whereas CAC scores of our cases fell within the top
decile CAC score range defined by the MESA cohort data
[48, 49]. While SNP Set-2 (derived from our discovery
cohort) was highly predictive of advanced CAC in the FHS
replication cohort, its predictive power declined signifi-
cantly with cases that had lower CAC levels in the same
cohort.
Understanding the drivers of accelerated CAD patho-
genesis hold great potential for providing insights into
inflammatory and immune responses [67–69] beyond
conventional mediators (e.g., dysregulation of lipid
metabolism and blood pressure) [67, 70]. Excessive reac-
tive oxygen species (ROS) generation has been previously
linked to high CAC levels [71, 72] and vascular aging [73].
Through ROS activity, macrophages that contain lipid
molecules (or foam cells) accumulate in the artery walls
and promote atherosclerosis [74]. EMR2 is a network
gene that promotes the release of inflammatory cytokines
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Table 4 Enriched diseases and biological functions (in the network of genes derived from GeneMANIA) with p-values ranging
between 1.0E-4 and 1.0E-2 as identified by IPA based on Fisher’s exact test
Category Disease or function Genes p-value
Connective tissue development and function Quantity of adipose tissue ARID5B, CYB5R4 3.58E-4
RETN, TLR5
Connective tissue development and function Differentiation of adipocytes ARID5B, EGLN1 8.82E-4
NIPBL, RETN
Cardiovascular disease Angiectasis of blood vessel EGLN1 9.87E-4
Cardiovascular system development and function Area of capillary vessel EGLN1 9.87E-4
Hematological system development and function Cell division of AIMP1 9.87E-4
peripheral blood lymphocytes
Cardiovascular disease, endocrine system disorders, Susceptibility to insulin RETN 9.87E-4
Metabolic disease resistance-related hypertension
Cardiac necrosis, cell death and survival Cell death of heart tissue EGLN1 1.97E-3
Cellular movement Migration of connective tissue cells AIMP1, ARID5B 2.14E-3
RETN
Carbohydrate metabolism, cellular function Homeostasis of D-glucose CYB5R4, RETN 2.46E-3
and maintenance TLR5
Nucleic acid metabolism Conversion of NAD+ NNT 2.96E-3
Cardiovascular system development and function Tethering of endothelial cell lines FUT3 2.96E-3
Cellular compromise, inflammatory response Degranulation of beta islet cells CYB5R4 3.94E-3
Cardiovascular system development and function Density of blood vessel tissue AIMP1 3.94E-3
Endocrine system disorders, hematological disease Onset of hyperglycemia CYB5R4 3.94E-3
Metabolic disease
Carbohydrate metabolism Tolerance of D-glucose CYB5R4 4.93E-3
Cardiovascular system development and function Angiogenesis of heart EGLN1 5.91E-3
Cardiovascular system development and function Density of blood vessel AIMP1, EGLN1 5.96E-3
Immune cell trafficking, inflammatory response Adhesion of neutrophils ADGRE2 (EMR2) 7.52E-3
Hematological system development and function TLR5
Endocrine system development and function Insulin sensitivity of liver RETN 7.87E-3
Hepatic system development and function
Nucleic acid metabolism Metabolism of NADPH CYB5R4 7.87E-3
Connective tissue development and function Quantity of visceral fat RETN 8.85E-3
Carbohydrate metabolism Binding of chondroitin sulfate ADGRE2 (EMR2) 9.83E-3
51 additional enriched diseases and biological functions (statistically less significant) with p-values ranging between 1.0E-2 and 5.0E-2 are listed in Additional file 1: Table S7
from macrophages and has been reported to be highly
expressed in foamy macrophages handling lipid overload
in atherosclerotic vessels [75]. Excessive ROS generation
also leads to reduced bioactivity of nitric oxide (NO) [76],
which is a cardioprotective molecule. The reduced form of
NADP (NADPH) is required for the synthesis of choles-
terol [77] as a cofactor in all reduction reactions. It is
also required for the regeneration of reduced glutathione
(GSH) [78] that provides protection against ROS activ-
ity [79]. Two of our network genes, NNT (associated with
diabetes in mice [80]) and CYB5R4, are both involved
in NADPH metabolism. As key elements of NADPH
metabolism, NADPH oxidases generate ROS and are con-
sidered as therapeutic targets against vascular aging [81].
NADPH oxidase activity has been shown to modulate
atherosclerosis in mice [82].
Among our network genes previously associated
with arterial aging, TLR5 is a member of the TLR
(toll-like receptor) family, which is an established
mediator of atherosclerosis [83] due to its role in
immune response through the induction of inflamma-
tory cytokines [84]. RETN is a biomarker for metabolic
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syndrome. Its overexpression has been shown to lead to
increased atherosclerotic progression in mice [85]. Sim-
ilarly, inhibition of EGLN1 has been shown to provide
protection against atherosclerosis in mice by improving
glucose and lipid metabolism and reducing inflamma-
tion and decreasing the areas of atherosclerotic plaque
[86]. HIF1-alpha proteins, which are modulated by
EGLN1, are established regulators of inflammation and
atherosclerosis [87].
NRG3 is a network gene that is a member of the
neuregulin family. Another member of this family is
NRG1, which has been shown to inhibit atherogenesis
and macrophage foam cell formation in a human study
[88]. It has also been shown to moderate the associa-
tion between job strain and atherosclerosis among men
[89]. Another network gene FOXN3 has been associ-
ated with fasting blood glucose, serum cholesterol, and
diabetes in past GWAS [90–92]. FOXN3 has also been
linked to carotid intima-media thickness (a subclinical
measure for atherosclerosis) and plaque in recent fine
mapping studies in humans [93, 94]. Taken together, our
findings show that several biological processes and risk
factors associated with cardiovascular disease, and partic-
ularly with vascular aging, are enriched within the net-
work we derived from the loci of SNPs that are highly
predictive of advanced CAC. Vascular aging is highly
relevant to CAC since aged vascular smooth muscle
cells (VSMCs) are known to have less resistance against
phenotypic modulations that promote vascular calcifi-
cation [95]. In fact, along with seven traditional risk
factors (age, gender, total cholesterol, HDL cholesterol,
systolic BP, smoking status, hypertension medication sta-
tus), the Agatston CAC score is used as a parameter
in quantifying “vascular age” in the MESA arterial age
calculator [96].
Dividing case subjects into subcategories based on the
level of disease measured by different measures such as
CAC scores, to pursue subphenotype-specific models [67]
is a potentially effective approach for studying heart dis-
ease phenotypes. In this predictive modeling study, we
focused on case subjects within the 89th-99th percentile
CAC score range and age-matched controls in two patient
cohorts. The replication of highly predictive loci identi-
fied from the ClinSeq discovery cohort in the FHS cohort
and the fact that we observe enrichment of several biolog-
ical processes previously linked to cardiovascular disease
at the network level demonstrates the effectiveness of our
machine learning based approach. Our analysis provides a
candidate list for conventional genotype-phenotype asso-
ciation studies of advanced CACwithout the genomewide
multiple testing penalty, thereby illustrating the comple-
mentary utility of machine learning and regression-based
methods that can provide inputs to each other for follow-
up studies.
Conclusions
We used a combination of clinical and genotype data
for predictive modeling of advanced coronary calcium.
Machine learning models trained with SNP Set-2 (iden-
tified from the ClinSeq discovery cohort) produced high
predictive performance in the FHS replication cohort.
Upon identifying a subset of 21 SNPs from this set that
led to optimal predictive performance in both cohorts, we
developed NN models trained with the ClinSeq genotype
data. We tested these models with the FHS genotype data
and obtained high predictive accuracy values (AUC=0.80-
0.85) under a wide range of network topologies, thereby
replicating the collective predictive ability of these SNPs
in FHS. At the gene network level, several biological pro-
cesses previously linked to cardiovascular disease, includ-
ing processes associated with accelerated “vascular aging”,
were found to be enriched among the predictive loci.
A potential extension of our modeling study is the
expansion of the panel of SNPs, which are highly predic-
tive of advanced CAC levels, around their loci for building
more comprehensive models. Subsequently, we would like
to test these potential predictors of rapid CAC progres-
sion and early onset of MI with longitudinal data in inde-
pendent cohorts, especially for cases poorly predicted by
traditional risk factors. To conclude, our study on CAC, a
cardiovascular disease phenotype and a predictive marker
of future cardiac events illustrates the potential of com-
bining multiple machine learning methods as informative
and accurate diagnostic tools. Our results also suggest that
utilizing markers specific to a limited range of coronary
calcium, rather than its complete spectrum, is an effec-
tive approach for building accurate predictive models for
personalized medicine efforts that require disease-level
specific risk prediction and prevention.
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